WO1999044990A1 - Novel process - Google Patents
Novel process Download PDFInfo
- Publication number
- WO1999044990A1 WO1999044990A1 PCT/SE1999/000318 SE9900318W WO9944990A1 WO 1999044990 A1 WO1999044990 A1 WO 1999044990A1 SE 9900318 W SE9900318 W SE 9900318W WO 9944990 A1 WO9944990 A1 WO 9944990A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction mixture
- flask
- ether
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000008569 process Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000006239 protecting group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- -1 prostaglandin compounds Chemical class 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 239000011541 reaction mixture Substances 0.000 description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 239000010410 layer Substances 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000003760 magnetic stirring Methods 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 10
- 239000003039 volatile agent Substances 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000003180 prostaglandins Chemical class 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 239000012267 brine Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000010626 work up procedure Methods 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 7
- JICGTNNQQNZRHZ-UHFFFAOYSA-N oct-1-yn-1-ol Chemical compound CCCCCCC#CO JICGTNNQQNZRHZ-UHFFFAOYSA-N 0.000 description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 5
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 5
- DLJKPYFALUEJCK-MRVZPHNRSA-N carboprost Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O DLJKPYFALUEJCK-MRVZPHNRSA-N 0.000 description 5
- 238000011097 chromatography purification Methods 0.000 description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 5
- 238000010907 mechanical stirring Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 4
- 229960003395 carboprost Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-M phthalate(1-) Chemical compound OC(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- QQCOAAFKJZXJFP-XAYIDPIISA-N 15-methyl-15R-PGF2alpha methyl ester Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC QQCOAAFKJZXJFP-XAYIDPIISA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- ZBDMJPAJZFSKPR-UHFFFAOYSA-N 3-methyloct-1-yn-3-ol Chemical compound CCCCCC(C)(O)C#C ZBDMJPAJZFSKPR-UHFFFAOYSA-N 0.000 description 2
- DHNDDRBMUVFQIZ-UHFFFAOYSA-N 4-hydroxycyclopent-2-en-1-one Chemical class OC1CC(=O)C=C1 DHNDDRBMUVFQIZ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000005828 desilylation reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- SNHOZPMHMQQMNI-UHFFFAOYSA-N lithium;2h-thiophen-2-ide Chemical compound [Li+].C=1C=[C-]SC=1 SNHOZPMHMQQMNI-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QVXSANNZCZLRJJ-UHFFFAOYSA-N methyl 7-(3-hydroxy-5-oxocyclopenten-1-yl)hept-5-ynoate Chemical compound COC(=O)CCCC#CCC1=CC(O)CC1=O QVXSANNZCZLRJJ-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid group Chemical group C(C=1C(C(=O)O)=CC=CC1)(=O)O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical class [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- ZBDMJPAJZFSKPR-SECBINFHSA-N (3s)-3-methyloct-1-yn-3-ol Chemical compound CCCCC[C@](C)(O)C#C ZBDMJPAJZFSKPR-SECBINFHSA-N 0.000 description 1
- UNBRKDKAWYKMIV-QWQRMKEZSA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 UNBRKDKAWYKMIV-QWQRMKEZSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- GULNLSGTYCQLLM-UHFFFAOYSA-N 3-hydroxycyclopentan-1-one Chemical compound OC1CCC(=O)C1 GULNLSGTYCQLLM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IUXFEADVRDBNQU-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxy-2-phenylselanylcyclopent-2-en-1-one Chemical compound CC(C)(C)[Si](C)(C)OC1CC(=O)C([Se]C=2C=CC=CC=2)=C1 IUXFEADVRDBNQU-UHFFFAOYSA-N 0.000 description 1
- DAPZSGCXUJECAI-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxycyclopent-2-en-1-one Chemical compound CC(C)(C)[Si](C)(C)OC1CC(=O)C=C1 DAPZSGCXUJECAI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241001282153 Scopelogadus mizolepis Species 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- XUTQYQHGALCMNU-UHFFFAOYSA-N [carboxy(propan-2-yl)amino]-propan-2-ylcarbamic acid Chemical compound CC(C)N(C(O)=O)N(C(C)C)C(O)=O XUTQYQHGALCMNU-UHFFFAOYSA-N 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XCIXKGXIYUWCLL-HOSYLAQJSA-N cyclopentanol Chemical class O[13CH]1CCCC1 XCIXKGXIYUWCLL-HOSYLAQJSA-N 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical compound [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000328 methylergometrine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SFDZETWZUCDYMD-UHFFFAOYSA-N monosodium acetylide Chemical compound [Na+].[C-]#C SFDZETWZUCDYMD-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- WWIISXZXDOQFBU-GFCCVEGCSA-N trimethyl-[(3s)-3-methyloct-1-yn-3-yl]oxysilane Chemical compound CCCCC[C@@](C)(C#C)O[Si](C)(C)C WWIISXZXDOQFBU-GFCCVEGCSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the present invention relates to novel process for the preparation of prostaglandin compounds which are useful as medicaments.
- Prostaglandins are a family of 20-carbon fatty acids found in virtually all mammalian cells and are biosynthesised from C-20 polyunsaturated fatty acids via cyclooxygenase enzyme system (S. Bergstroem., Science, 157, 382, 1967).
- PGs have been the focus of extensive efforts in synthetic chemistry.
- increasing attention is being focused on PG analogs.
- the nonavailability of suitable natural source coupled with their potential drug utility has led to the clinical development of a number of synthetic PG analogs.
- both pharmacologically and clinically are analogs incorporating methyl groups into the prostaglandin skeleton at C-1.5 (a).
- Carboprost is clinically listed for treatment of post partum haemorrage as an alternative to methylergometrine or where the latter has produced inadequate response.
- Intramuscular injection of 250 mg of carboprost in sterile aqueous solution is the best therapy now available, very successful in cases ready for uterectomy due to bleeding not stopped by methergin etc. This has been registered for this indication in Sweden and India (available under the brand names Prostinefem in Sweden and Prosodin in India).
- the most recent approach which is frequently used for the syntheses of PGs involves the conjugate addition of an organometallics to an ⁇ -substituted 4-hydroxy 2-cyclopentenone (M.P.L. Caton in "New Synthetic Routes to Prostaglandins"., Academic Press N.Y., pg 105, 1982 and F. Sato et al. dislike J. Org Chem., 59, 6153, 1994).
- the two-component process consists of two independent but complementary routes: introduction of a o-side chain to an endo-enone bearing an ⁇ -side chain and introduction of ⁇ -chain to an ex ⁇ -enone bearing an o-side chain.
- the present invention involves the use of enantiomerically pure e/ut ⁇ -enone (II) bearing an ⁇ -sidechain and the desired o-chain was introduced via conjugate addition of a higher order cuprate generated using an enantriomerically pure ⁇ -chain iodide (VI).
- the delineated process describes the synthesis of en_io-enone (II) in an excellent optical purity (> 99% ee), following the alkylation chemistry of the stabilised carbanion and its resolution using the technique of ultrasound mediated enzymatic irreversible transesterification.
- the invention therefore provides a process for the preparation of a compound of formula (I): HO * (I)
- R 1 and R 2 are both hydrogen or together form a bond such that the groups OR 1 and R 2 form a carbonyl group.
- R 1 and R 2 are both hydrogen.
- the groups P and P which can be the same or different, can be any suitable oxygen protecting groups, for example tetrahydropyran and, in particular, silyl protecting groups such as t-butyldiphenylsilyl, dimethylphenylsilyl, triethylsilyl, t-butyldimethylsilyl (TBDMS), trimethylsilyl (TMS) and triisopropylsilyl .
- P is TBDMS and P 1 is TMS.
- the reaction of compounds of formula (II) and (HI) is carried out in a suitable solvent such as THF-hexane, THF-ether, preferably THF/ether.
- a suitable solvent such as THF-hexane, THF-ether, preferably THF/ether.
- the reaction is carried out at reduced temperature, for example at about -78°C.
- the reaction is carried out in the presence of a Lewis acid, particularly in the presence of BF 3 .OE. 2 . It has been found that the use of BF 3 .OEt 2 not only activates the enone at low temperatures and drives the reaction to completion, but also circumvents the problem of dehydration at the C- 15 position.
- the higher order cuprate of formula (El) is preferably generated using anorgano- lithium reagent, preferably butyl lithium.
- Reduction of a compound of formula (IA) can be carried out using known reducing agents.
- reduction of the cyclopentanone is preferably carried out using a selective reducing agent such as K-selectride to give the desired cyclopentanol isomer.
- Reduction of the triple bond can be carried out using conventional techniques such as Lindlar hydrogenation.
- protecting groups P and P 1 are both silyl groups deprotection of both groups can be achieved using a fluoride reagent such as TBAF in a suitable solvent such as THF.
- a fluoride reagent such as TBAF
- THF a suitable solvent
- the cyclopentanone moiety is reduced, followed by deprotection of the groups P and P 1 followed by reduction of the triple bond to furnish the desired compounds of formula (I).
- Hal is halogen in the presence of an organolithium reagent.
- L is a group such as a -SePh to stabilise the carbanion generated and Hal is bromo or iodo, preferably iodo.
- Compounds of formula (IV) in which L is SePh can be prepared from the corresponding enone and phenylselenyl chloride using literature procedures.
- the enone can be prepared by protecting the corresponding alcohol, for example by treating with TBDMS chloride conventional conditions.
- the compound of formula (III) is a suitable cuprate, in particular a higher order cuprate and preferably a hienyl cuprate, in particular dilithium [3-methyl, 3-(trimethylsilyl)oxy octyl ⁇ - 2-thienyl cyanocuprate of formula (D3A):.
- Novel intermediates form a further aspect of the invention.
- the title compound was prepared from the above ⁇ -alcohol according to the method of Carl Johnson et al., JACS, 110, 4726-35 (1988) as an oil, bp 110 - 113°C at 0.9 mm Hg.
- the title compound was prepared according to the method of M. Minai, Jap. Patent., Kokai No. 62236, 1982.
- a 3-necked 31itre r.b. flask was cooled under a stream of nitrogen gas and was fitted with mechanical stirrer through the centre neck.
- Side arm was connected to a socket with gas inlet and a cold, finger condenser.
- Another side arm was connected to a nitrogen inlet under static pressure.
- the cold finger condenser was charged with dry ice-acetone mixture (-78°C) and the reaction flask was kept in an insulated bath.
- Anhydrous ammonia gas (dried through a wash bottle containing KOH pellets) was bubbled at a steady rate through the gas inlet in an atmosphere of nitrogen, whereupon ammonia condenses into the reaction flask. It took around 2 hr.
- the mother liquor from filitration was concentrated in vacuo using a rotary evaporator and kept in the refrigerator to get an additional lot of hemiphthalate ester (2 crop, 0.43 Kg, m p 61- 62°C).
- the compound obtained (0.151 Kg) showed higher m p and hence was kept aside and taken up for the recovery of racemic octynol. Yield of hemiphthalate ester: 1.348 Kg, 71%.
- the product was purified by silica gel chromatography eluting with ethyl acetate/petroleum ether. Yield of the pure product: 11.11 gm, 31.76 mmols, 70%.
- step b To the above solution of the lower order cuprate was added the solution of vinyl lithium (step b) dropwise by means of a cannula over a period of 10 min at -22°C, washed with THF (5 ml) and the solution stirred at -22°C for a further 1 hr. to provide a homogenous higher order cuprate (clear solution, pale yellowish orange colour). The resulting cuprate solution was cooled to -78°C (dry ice-acetone bath).
- This product was further purified by preparative reversed phase HPLC using a preparative ODS (C-18) SHIMPAK column (20 x 250 mm) and using a mobile phase of acetonitrite- water (1:1): UV detection: 210 nm.
- the preparative HPLC was done in batches of 0.170 gm and the recovery of the pure carbonprost methyl ester of USP specifications was ⁇ 65%.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9908511-9A BR9908511A (en) | 1998-03-06 | 1999-03-04 | Process for the preparation of a compound, e, compound |
CA002327332A CA2327332A1 (en) | 1998-03-06 | 1999-03-04 | Novel process |
KR1020007009831A KR20010041632A (en) | 1998-03-06 | 1999-03-04 | Novel Process |
JP2000534534A JP2002505321A (en) | 1998-03-06 | 1999-03-04 | New manufacturing method |
HU0102710A HUP0102710A2 (en) | 1998-03-06 | 1999-03-04 | Novel process for the preparation of prostaglandine compounds |
EP99908058A EP1075464A1 (en) | 1998-03-06 | 1999-03-04 | Novel process |
AU27572/99A AU2757299A (en) | 1998-03-06 | 1999-03-04 | Novel process |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN465/MAS/98 | 1998-03-06 | ||
IN465MA1998 | 1998-03-06 | ||
SE9801369A SE9801369D0 (en) | 1998-04-20 | 1998-04-20 | Novel process |
SE9801369-1 | 1998-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999044990A1 true WO1999044990A1 (en) | 1999-09-10 |
Family
ID=26324795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/000318 WO1999044990A1 (en) | 1998-03-06 | 1999-03-04 | Novel process |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1075464A1 (en) |
JP (1) | JP2002505321A (en) |
KR (1) | KR20010041632A (en) |
CN (1) | CN1292780A (en) |
AU (1) | AU2757299A (en) |
BR (1) | BR9908511A (en) |
CA (1) | CA2327332A1 (en) |
HU (1) | HUP0102710A2 (en) |
WO (1) | WO1999044990A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385819A1 (en) * | 2001-05-08 | 2004-02-04 | Yonsung Fine Chemical Co. Ltd | Process for preparing prostaglandin derivatives and stereospecific starting material thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102336693B (en) * | 2010-07-21 | 2014-01-22 | 上海天伟生物制药有限公司 | Carboprost tromethamine crystals, preparation method and application thereof |
CN102816099A (en) * | 2011-06-09 | 2012-12-12 | 上海天伟生物制药有限公司 | High-purity carboprost tromethamine, and preparation method and application thereof |
CN104860860B (en) * | 2015-04-29 | 2017-09-19 | 东北制药集团股份有限公司 | A kind of method for preparing purified of card prostatitis ester |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3728382A (en) * | 1970-05-04 | 1973-04-17 | Upjohn Co | 15-methyl and 15-ethyl prostaglandin analogs |
FR2180099A1 (en) * | 1972-04-14 | 1973-11-23 | Searle & Co | |
US3822303A (en) * | 1971-10-19 | 1974-07-02 | E Yankee | Trimethyl silyl esters of prostaglandin e acids and esters and process therefor |
US4029691A (en) * | 1974-05-01 | 1977-06-14 | The Upjohn Company | Prostaglandin A1 , analogs |
EP0178139A2 (en) * | 1984-10-08 | 1986-04-16 | Teijin Limited | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof |
US5447865A (en) * | 1992-06-10 | 1995-09-05 | Amprost Pharmaceutical, Inc. | Method of resolution of hydroxy substituted cyclopentanone enantiomers using lipase and lithium salt complexation |
-
1999
- 1999-03-04 CA CA002327332A patent/CA2327332A1/en not_active Abandoned
- 1999-03-04 AU AU27572/99A patent/AU2757299A/en not_active Abandoned
- 1999-03-04 KR KR1020007009831A patent/KR20010041632A/en not_active Application Discontinuation
- 1999-03-04 JP JP2000534534A patent/JP2002505321A/en active Pending
- 1999-03-04 HU HU0102710A patent/HUP0102710A2/en unknown
- 1999-03-04 BR BR9908511-9A patent/BR9908511A/en not_active IP Right Cessation
- 1999-03-04 CN CN998037257A patent/CN1292780A/en active Pending
- 1999-03-04 EP EP99908058A patent/EP1075464A1/en not_active Withdrawn
- 1999-03-04 WO PCT/SE1999/000318 patent/WO1999044990A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3728382A (en) * | 1970-05-04 | 1973-04-17 | Upjohn Co | 15-methyl and 15-ethyl prostaglandin analogs |
US3822303A (en) * | 1971-10-19 | 1974-07-02 | E Yankee | Trimethyl silyl esters of prostaglandin e acids and esters and process therefor |
FR2180099A1 (en) * | 1972-04-14 | 1973-11-23 | Searle & Co | |
US4029691A (en) * | 1974-05-01 | 1977-06-14 | The Upjohn Company | Prostaglandin A1 , analogs |
EP0178139A2 (en) * | 1984-10-08 | 1986-04-16 | Teijin Limited | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof |
US5447865A (en) * | 1992-06-10 | 1995-09-05 | Amprost Pharmaceutical, Inc. | Method of resolution of hydroxy substituted cyclopentanone enantiomers using lipase and lithium salt complexation |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Volume 109, No. 11, 12 Sept. 1988, (Columbus, Ohio, USA), page 672, Abstract No. 92636g; & JP 62195358 A (TANAKA TOSHIO et al.) 28 August 1987. * |
CHEMICAL ABSTRACTS, Volume 94, No. 11, 16 March 1981, (Columbus, Ohio, USA), LIU TSE-LI et al., "Syntheses of 15(R,S)-15-Methylprostaglandin E2 Methyl Esters and its 11-Methyl Ether Derivatives by 1,4-Addition of an Organocopper Reagent", page 681, Abstract No. 83648g; & K'O HSUEH T'UNG PAO, 1980, 25(5), 712-713. * |
J. AM. CHEM. SOC., Volume 112, 1990, BRUCE H. LIPSHUTZ et al., "Hydrozirconation-Transmetalation. A Mild, Direct Route to Higher Order Vinylic Cuprates from Monosubstituted Acetylenes", pages 7440-7441. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385819A1 (en) * | 2001-05-08 | 2004-02-04 | Yonsung Fine Chemical Co. Ltd | Process for preparing prostaglandin derivatives and stereospecific starting material thereof |
EP1385819A4 (en) * | 2001-05-08 | 2005-01-26 | Yonsung Fine Chemical Co Ltd | Process for preparing prostaglandin derivatives and stereospecific starting material thereof |
Also Published As
Publication number | Publication date |
---|---|
HUP0102710A2 (en) | 2001-12-28 |
CN1292780A (en) | 2001-04-25 |
JP2002505321A (en) | 2002-02-19 |
AU2757299A (en) | 1999-09-20 |
CA2327332A1 (en) | 1999-09-10 |
BR9908511A (en) | 2000-11-21 |
EP1075464A1 (en) | 2001-02-14 |
KR20010041632A (en) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2099814A (en) | 15-deoxy-16-hydroxy prostaglandins | |
Wilson et al. | Stereoselective phosphine-catalyzed synthesis of highly functionalized diquinanes. | |
EP1075464A1 (en) | Novel process | |
JP6643308B2 (en) | Metal-catalyzed asymmetric 1,4-conjugate addition of vinyl boron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones to yield prostaglandins and prostaglandin analogs | |
TANAKA et al. | Synthesis of 7-thiaprostaglandin E1 congeners: potent inhibitors of platelet aggregation | |
EP0178139B1 (en) | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof | |
JP2018529781A (en) | Method for total synthesis of Resolvin E1 | |
KR19980702884A (en) | Process for preparing prostaglandins E1, E2 and analogs thereof using furylcopper reagent | |
JP4153998B2 (en) | Method for producing prostaglandins | |
CZ20003234A3 (en) | Novel process | |
Arnold | Phosphoramidites as ligands for copper in catalytic asymmetric CC bond formation reactions with organozinc reagents | |
JP2713333B2 (en) | Isocarbacyclines and process for producing the same | |
KR920004190B1 (en) | Process for the preparation of 7-thiaprostaglandin e1 | |
JP2637339B2 (en) | Process for producing 2,3-disubstituted-4-substituted cyclopentanones | |
US5206416A (en) | Isocarbacyclin derivative | |
JPH062695B2 (en) | Method for producing isocarbacyclines | |
JPS62195358A (en) | Production of (5e)-prostaglandin e2 or such | |
JPS5838433B2 (en) | Method for producing phenyl-substituted PGF↓2-type compounds | |
JPS61189246A (en) | Production of 2,3-di-substituted-4-substituted cyclopentanone | |
White | Asymmetric Synthesis of Prostaglandins | |
JPH064557B2 (en) | Process for producing 2,3-disubstituted-4-substituted cyclopentanones | |
JPH0680024B2 (en) | Method for producing isocarbacyclines | |
JPS6061564A (en) | 6-nitroprostaglandin f, its preparation and use | |
JPS6156163A (en) | Preparation of (5e)-prostaglandin e2 | |
JPS647063B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99803725.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09284522 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2327332 Country of ref document: CA Ref document number: 2327332 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007009831 Country of ref document: KR Ref document number: PV2000-3234 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999908058 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999908058 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-3234 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007009831 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-3234 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999908058 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007009831 Country of ref document: KR |